Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12534778 | 0.92 | CRHR1 (0.53) | CRHR1SMN1; SMN2MAP2K7TDP1 | |
| SCHEMBL12534798 | 0.91 | CRHR1 (0.43) | CRHR1MAP2K7 | |
| SCHEMBL12534773 | 0.91 | CRHR1 (0.43) | CRHR1SMN1; SMN2MAP2K7 | |
| SCHEMBL12534794 | 0.90 | CRHR1 (0.45) | CRHR1SMN1; SMN2MAP2K7 | |
| SCHEMBL12534782 | 0.90 | CRHR1 (0.44) | CRHR1SMN1; SMN2MAP2K7TDP1 | |
| SCHEMBL1636170 | 0.87 | CRHR1 (0.48) | CRHR1SMN1; SMN2MAP2K7TDP1 | |
| SCHEMBL12534851 | 0.87 | CRHR1 (0.49) | CRHR1SMN1; SMN2TDP1 | |
| SCHEMBL12534771 | 0.86 | CRHR1 (0.64) | CRHR1MAP2K7TDP1 | |
| SCHEMBL1637967 | 0.85 | CRHR1 (0.47) | CRHR1SMN1; SMN2MAP2K7TDP1 | |
| SCHEMBL12535252 | 0.84 | KDM4E (0.30) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455511-B2 | Pyrrolopyridine derivatives substituted with cyclic amino group | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| US-20110130364-A1 | PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-02 | — | — | US | disclosed |
| US-7932259-B2 | Pyrrolo[2,3-d]pyrimidine derivatives substituted with a cyclic amino group | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20080287397-A1 | Pyrrolopyrimidine Derivatives Substituted with Cyclic Amino Group | TASHO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287397-A1 | Pyrrolopyrimidine Derivatives Substituted with Cyclic Amino Group | HRH2, HRH4, CRHR1 | CRHR1 3/4885SMN1; SMN2 3792/4885MAP2K7 1653/4885 |
| US-20110130364-A1 | PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | HRH2, HRH4, CRHR1 | CRHR1 3/4885SMN1; SMN2 3792/4885MAP2K7 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.